In Cancer immunotherapy, mAbs can be used as checkpoint inhibitors for example programmed cell death 1 ligand 1 (PD-L1) antibody and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). This evidence concerns the gene CD274 and cancer.